NCT06291207 A Study to Evaluate the Efficacy and Safety of AD-224
| NCT ID | NCT06291207 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Addpharma Inc. |
| Condition | Hypertension,Essential |
| Study Type | INTERVENTIONAL |
| Enrollment | 252 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 252 participants in total. It began in 2024-04-15 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-224
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied
Contact & Investigator
InHo Chae, M.D., Ph.D
PRINCIPAL INVESTIGATOR
Seoul National University Bundang Hospital
Frequently Asked Questions
Who can join the NCT06291207 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Hypertension,Essential. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06291207 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 252 participants.
Is NCT06291207 currently recruiting?
Yes, NCT06291207 is actively recruiting participants. Contact the research team at parkje@addpharma.co.kr for enrollment information.
Where is the NCT06291207 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT06291207 clinical trial?
NCT06291207 is sponsored by Addpharma Inc.. The principal investigator is InHo Chae, M.D., Ph.D at Seoul National University Bundang Hospital. The trial plans to enroll 252 participants.